OnKure director granted 1,275 stock options

OnKure Therapeutics, Inc. director Liam Ratcliffe received a grant of stock options covering 1,275 shares of Class A common stock.

Accepted by SEC EDGAR 06/08/2026 - 06:27 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. director Liam Ratcliffe received a grant of stock options covering 1,275 shares of Class A common stock. The options have an exercise price of $4.3000 per share and expire on June 3, 2036. According to the vesting terms, 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the issuer's next annual meeting of stockholders, provided he continues as a service provider through the vesting date. Following this grant, he holds 1,275 derivative securities directly in this option award.

Insider Trade Summary

Grant/Award: 1,275 shares

Grant/Award 1 txn

Insider Ratcliffe Liam

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	1,275	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 1,275 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Key Figures

Option grant size: 1,275 shares Exercise price: $4.3000 per share Expiration date: June 3, 2036 +3 more

6 metrics

Option grant size 1,275 shares Stock Option (right to buy) granted to director on June 4, 2026

Exercise price $4.3000 per share Conversion or exercise price for the stock option

Expiration date June 3, 2036 Option term end for the 1,275-share grant

Vesting date June 4, 2027 or earlier 100% vests on earlier of June 4, 2027 or day before next annual meeting

Post-grant holdings 1,275 derivative securities Total shares following transaction in this option award

Transaction price $0.0000 Reporting price per derivative share for the grant

Key Terms

Stock Option (right to buy), Class A Common Stock, exercise price, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion_or_exercise_price: 4.3000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders"

vesting date financial

"subject to the Reporting Person continuing as a service provider through the applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OnKure Therapeutics (OKUR) director Liam Ratcliffe receive in this Form 4?

Director Liam Ratcliffe received a stock option grant for 1,275 shares of Class A common stock. The award is reported as a derivative security and represents a compensation-related acquisition, not an open-market stock purchase or sale.

What is the exercise price of Liam Ratcliffe’s OnKure Therapeutics (OKUR) stock options?

The stock options have an exercise price of $4.3000 per share. This is the price at which he can purchase OnKure Therapeutics Class A common stock if and when the options are vested and exercised.

When do Liam Ratcliffe’s OnKure Therapeutics (OKUR) options vest?

All 1,275 option shares vest 100% on the earlier of June 4, 2027 or the day before OnKure Therapeutics’ next annual meeting. Vesting requires that he continues as a service provider through the applicable vesting date.

When do the reported OnKure Therapeutics (OKUR) stock options expire?

The options reported in this Form 4 expire on June 3, 2036. After this expiration date, any unexercised portion of the 1,275-share option grant can no longer be exercised to purchase Class A common stock.

How many OnKure Therapeutics (OKUR) derivative securities does Liam Ratcliffe hold after this transaction?

Following this grant, he holds 1,275 derivative securities related to this option award. The Form 4 shows total shares following the transaction of 1,275, all held directly as stock options tied to Class A common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ratcliffe Liam

(Last) (First) (Middle)

C/O ONKURE THEREAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.3	06/04/2026		A		1,275		(1)	06/03/2036	Class A Common Stock	1,275	$0	1,275	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

	/s/ Rogan Nunn, by power of attorney	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)